接受药物血栓预防的非ICU住院COVID-19患者深静脉血栓发生率
研究对84例连续非ICU住院COVID-19患者行下肢静脉压迫超声筛查深静脉血栓,所有患者均接受依诺肝素或磺达肝癸钠药物血栓预防。深静脉血栓发生率为11.9%(95%CI 4.98-18.82),其中近端2例(2.4%,95%CI -0.87-5.67)、远端8例(9.5%,95%CI 3.23-5.77)。作者结论认为非ICU住院COVID-19患者尽管接受指南推荐血栓预防仍可能发生深静脉血栓。
要点
- 84例非ICU住院COVID-19患者接受药物血栓预防,深静脉血栓发生率为11.9%(95%CI 4.98-18.82)。
- 10例深静脉血栓中近端2例(2.4%)、远端8例(9.5%)。
- D-二聚体>3000 µg/L、当前或既往肿瘤、需高流量鼻氧和/或NIV与深静脉血栓显著相关。
核心结论
- 作者结论认为,非ICU住院COVID-19患者尽管接受指南推荐血栓预防,仍可能发生深静脉血栓。
研究设计与样本
- 对连续非ICU住院COVID-19患者进行下肢静脉压迫超声系统筛查深静脉血栓,不依赖有无深静脉血栓体征或症状。
- 筛查人群为84例连续患者,平均年龄67.6±13.5岁,平均Padua预测评分5.1±1.6。
- 所有患者均接受依诺肝素或磺达肝癸钠药物血栓预防。
主要发现
- 72例患者(85.7%)存在呼吸功能不全、需要氧疗、活动减少或卧床。
- 共发现10例深静脉血栓,发生率为11.9%(95%CI 4.98-18.82)。
- 10例中近端深静脉血栓2例(发生率2.4%,95%CI -0.87-5.67),远端深静脉血栓8例(发生率9.5%,95%CI 3.23-5.77)。
- 有与无深静脉血栓受试者之间的显著差异包括D-二聚体>3000 µg/L(P < .05)、当前或既往肿瘤(P < .05)、需要高流量鼻氧治疗和/或NIV(P < .01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A remarkably high incidence of venous thromboembolism (VTE) has been reported among critically ill patients with COVID-19 assisted in the intensive care unit (ICU). However, VTE burden among non-ICU patients hospitalized for COVID-19 that receive guideline-recommended thromboprophylaxis is unknown. OBJECTIVES: To determine the incidence of VTE among non-ICU patients hospitalized for COVID-19 that receive pharmacological thromboprophylaxis. METHODS: We performed a systematic screening for the diagnosis of deep vein thrombosis (DVT) by lower limb vein compression ultrasonography (CUS) in consecutive non-ICU patients hospitalized for COVID-19, independent of the presence of signs or symptoms of DVT. All patients were receiving pharmacological thromboprophylaxis with either enoxaparin or fondaparinux. RESULTS: The population that we screened consisted of 84 consecutive patients, with a mean age of 67.6 ± 13.5 years and a mean Padua Prediction Score of 5.1 ± 1.6. Seventy-two patients (85.7%) had respiratory insufficiency, required oxygen supplementation, and had reduced mobility or were bedridden. In this cohort, we found 10 cases of DVT, with an incidence of 11.9% (95% confidence interval [CI] 4.98-18.82). Of these, 2 were proximal DVT (incidence rate 2.4%, 95% CI -0.87-5.67) and 8 were distal DVT (incidence rate 9.5%, 95% CI 3.23-5.77). Significant differences between subjects with and without DVT were D-dimer > 3000 µg/L (P < .05), current or previous cancer (P < .05), and need of high flow nasal oxygen therapy and/or non-invasive ventilation (P < .01). CONCLUSIONS: DVT may occur among non-ICU patients hospitalized for COVID-19, despite guideline-recommended thromboprophylaxis.
引用
- Santoliquido A, Porfidia A, Nesci A, et al. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. J Thromb Haemost. 2020. PMID: 32633068. doi:10.1111/jth.14992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。